December 10, 2013
by admin
13 Comments
There is a theme behind many of DrugBaron’s musings over the last three years: pharma R&D is just too expensive to make economic sense. Given high failure rates throughout the process, including in particular a significant rate of late stage … Continue reading
December 9, 2013
by admin
0 comments
“So DrugBaron tells me that drug discovery and early stage development is essentially random, and so all I have do is cut costs to the bone. Then if I have enough shots on goal, even if I don’t really know … Continue reading
October 24, 2013
by admin
12 Comments
The asset-centric platform at Index Ventures is built around stringency. The entire concept arose from the realization that drug discovery and development is a complex process, in a low-validity environment (meaning there is often too little data available to make … Continue reading